Sakar Healthcare

Sakar Healthcare delivered a strong Q4 FY26 with revenue of ₹71.1 croreCurrent reported value: ₹71.1 crore. No comparable prior figure is available in the source record. (+42Current reported value: 42. No comparable prior figure is available in the source record.% YoY), EBITDA of ₹26.2 croreCurrent reported value: ₹26.2 crore. No comparable prior figure is available in the source record. (37Current reported value: 37. No comparable prior figure is available in the source record.% margin), and PAT of ₹11.0 croreCurrent reported value: ₹11.0 crore. No comparable prior figure is available in the source record. (+91Current reported value: 91. No comparable prior figure is available in the source record.% YoY). The oncology division contributed 38%Current 38%. Reported change: +17pp YoY. of full-year revenue, up from 21% last year, driven by domestic growth and initial export traction. Management guided for ~40% revenue growth in FY27, targeting oncology revenue to double to ~₹200 crore, supported by 60+ signed contracts, 125 dossier filings, and tech transfers with Accord, Torrent, and others. The oncology facility (capacity utilization <30%Current <30%. Reported change: flat.) can scale to ₹800-1,000 crore with minimal capex. Risks include lumpy export order patterns and potential delays in regulatory approvals for the remaining seven Accord products.